Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Recurrence 2Leukemia, Myeloid 2Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × zosuquidar trihydrochloride × Clear all
NCT00129168 2008-04-01

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

Kanisa Pharmaceuticals

Phase 1/2 Completed
100 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute

NCT00233909 2008-04-01

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Kanisa Pharmaceuticals

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡